Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mindbio Therapeutics Corp. ( (TSE:MBIO) ) has shared an update.
MindBio Therapeutics Corp. has issued 3,428,571 common share purchase warrants to Haywood Securities as part of a strategic investment and advisory services agreement. This move is expected to support MindBio’s ongoing clinical trials and research in psychedelic medicine development, potentially enhancing its market position and offering novel treatments for mental health conditions.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a clinical stage biopharmaceutical company focused on developing novel treatments for mental health conditions. It is a leader in the microdosing of psychedelic medicines, with its lead candidate drug, MB22001, being a proprietary form of LSD designed for take-home microdosing. The company is advancing its drug and technology protocols through clinical trials, including Phase 2B trials for cancer patients with existential distress and patients with Major Depressive Disorder. MindBio is also involved in digital therapeutics and has completed Phase 1 and 2a clinical trials with positive results.
YTD Price Performance: -50.0%
Average Trading Volume: 103,913
Technical Sentiment Signal: Strong Buy
For detailed information about MBIO stock, go to TipRanks’ Stock Analysis page.